Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.54 USD | -1.28% | -.--% | +79.28% |
Business Summary
Number of employees: 138
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Woodhouse
CEO | Chief Executive Officer | 54 | 15-03-01 |
William Rieflin
CHM | Chairman | 64 | 10-08-31 |
Daniel Kaplan
CTO | Chief Tech/Sci/R&D Officer | - | 07-12-31 |
William Chang
CTO | Chief Tech/Sci/R&D Officer | - | 19-01-31 |
Hsiao Lieu
CTO | Chief Tech/Sci/R&D Officer | 53 | 19-02-28 |
Valerie Pierce
CMP | Compliance Officer | 61 | 19-10-28 |
David Goeddel
BRD | Director/Board Member | 72 | 07-12-31 |
Joyce Q. Acbay
LAW | General Counsel | - | 20-03-31 |
Irene Perlich
AUD | Comptroller/Controller/Auditor | - | 21-02-28 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Roger Perlmutter
BRD | Director/Board Member | 71 | 21-06-07 |
David Goeddel
BRD | Director/Board Member | 72 | 07-12-31 |
William Rieflin
CHM | Chairman | 64 | 10-08-31 |
David Woodhouse
CEO | Chief Executive Officer | 54 | 15-03-01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 83,462,408 | 81,886,322 ( 98.11 %) | 0 | 98.11 % |
Company contact information
NGM Biopharmaceuticals, Inc.
333 Oyster Point Boulevard
94080-7014, South San Francisco
+650 243 5555
http://www.ngmbio.comSector
1st Jan change | Capi. | |
---|---|---|
+79.28% | 129M | |
+8.63% | 115B | |
+13.17% | 107B | |
-12.76% | 22.31B | |
-3.99% | 21.6B | |
-7.19% | 18.23B | |
-39.93% | 17.62B | |
+6.67% | 14.26B | |
+33.90% | 12.37B | |
-28.60% | 8.28B |
- Stock Market
- Equities
- NGM Stock
- Company NGM Biopharmaceuticals, Inc.